Cargando…
De-escalation yes, but not at the expense of efficacy: in defense of better treatment
Autor principal: | Shapiro, Charles L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690937/ https://www.ncbi.nlm.nih.gov/pubmed/31428678 http://dx.doi.org/10.1038/s41523-019-0120-z |
Ejemplares similares
-
Adjuvant chemotherapy for node negative, high Recurrence Score(TM) breast cancer: in defense of de-escalation
por: Lake, Diana, et al.
Publicado: (2019) -
De-escalation in breast cancer surgery
por: Shubeck, Sarah P., et al.
Publicado: (2022) -
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019) -
Fluid removal tolerance during the de-escalation phase: is preload unresponsiveness the best guiding candidate?
por: Ruste, Martin, et al.
Publicado: (2023) -
Escalating burden of SARS-CoV-2 infection in Ethiopia
por: Adane, Kelemework, et al.
Publicado: (2021)